%0 Journal Article %A Cox, Dermot %A Maree, Andrew O. %A Dooley, Michelle %A Conroy, RonĂ¡n %A Byrne, Michael F. %A Fitzgerald, Desmond J. %D 2019 %T Effect of enteric coating on antiplatelet activity of low-dose aspirin in healthy volunteers. %U https://repository.rcsi.com/articles/journal_contribution/Effect_of_enteric_coating_on_antiplatelet_activity_of_low-dose_aspirin_in_healthy_volunteers_/10781426 %2 https://repository.rcsi.com/ndownloader/files/19294724 %K Adult %K Aspirin %K Body Weight %K Cross-Over Studies %K Dipyridamole %K Dose-Response Relationship %K Drug %K Drug Combinations %K Humans %K Logistic Models %K Middle Aged %K Platelet Aggregation %K Platelet Aggregation Inhibitors %K Reference Values %K Tablets %K Enteric-Coated %K Therapeutic Equivalency %K Thromboxane B2 %K Treatment Outcome %K Clinical Pharmacology and Therapeutics %X

BACKGROUND AND PURPOSE: Aspirin resistance may be relatively common and associated with adverse outcome. Meta-analysis has clearly shown that 75 mg plain aspirin is the lowest effective dose; however, it is not known whether the recent increased use of enteric-coated aspirin could account for aspirin resistance. This study was designed to determine whether enteric-coated aspirin is as effective as plain aspirin in healthy volunteers. METHODS: Seventy-one healthy volunteers were enrolled in 3 separate bioequivalence studies. Using a crossover design, each volunteer took 2 different aspirin preparations. Five aspirin preparations were evaluated, 3 different enteric-coated 75-mg aspirins, dispersible aspirin 75 mg and asasantin (25-mg standard release aspirin plus 200-mg modified-release dipyridamole given twice daily). Serum thromboxane (TX) B2 levels and arachidonic acid-induced platelet aggregation were measured before and after 14 days of treatment. RESULTS: All other aspirin preparations tested were inferior to dispersible aspirin (P99%) inhibition (P

%I Royal College of Surgeons in Ireland